Advanced melanoma has the highest percase rate of brain metastases but accounts for the third most frequent cause of death from brain metastases, because lung and breast cancers, with lower per-case rates, are far more common. Historically, solid tumor brain metastases were treated based on retrospective reports of pooled tumors, predominantly lung, breast, and melanoma, but recent therapeutic advances in all three diseases now require separate approaches to therapy and scientific investigation. The review by Chukwueke et al 1 discusses current therapies and the clinical basis for their use. A more in-depth description of the science, the mechanisms of action, and approaches to overcome therapy resistance is beyond the scope of their review. It is critical, however, to learn more about when and how melanoma cells become capable of trafficking to and invading the brain, how they grow and resist apoptosis, and how they can evade therapies that may be active in the patient's extracranial disease.
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The existing literature about risks and prognosis for brain metastases is composed of reports that range from basic molecular studies through genetically engineered animal models to purely clinical associations of brain metastases with other patient and tumor characteristics. In the present review, some of the authors' conclusions require further explanation or alternative interpretations. For example, whole-brain radiotherapy in melanoma is waning because of its poor control of metastases rather than the risk of long-term neurocognitive decay, except perhaps in patients considered for prophylactic whole-brain radiotherapy after stereotactic radiosurgery for single or oligometastatic disease. Patients with multiple metastases who are not candidates for stereotactic radiosurgery and are referred for whole-brain radiotherapy rarely survive long enough for late radiation toxicities-usually succumbing to extracranial and/or CNS progression, the latter potentially indistinguishable from neurotoxicity resulting from radiotherapy.
Although agents used historically for metastatic melanoma probably failed to cross an intact blood-brain barrier, the principal reason for their poor results is low antitumor activity. Although temozolomide, a dacarbazine-like agent approved for primary brain malignancies, had high CNS penetrance, its low activity against melanoma with brain metastases confirmed that merely entering the brain is not sufficient for a drug to be effective there. 2 Recent advances reflect changes in the treatment paradigm: ipilimumab, a human antibody against cytotoxic T-lymphocyte antigen-4, and pembrolizumab, a humanized antibody targeting programmed death-1, have both shown single-agent activity against melanoma metastatic to the brain, 3, 4 and combinations targeting both immune checkpoints are under investigation. 5 Because immunoglobulin molecules do not cross the blood-brain barrier but lymphocytes do, 6 further testing of like co-stimulating antibodies or inhibitors of immunosuppression in the tumor microenvironment, are warranted. In addition to immunotherapy, recent trials have shown that the BRAF inhibitors, which cross the intact blood-brain barrier poorly, have substantial activity against BRAF-mutated melanoma metastatic to the brain, 7, 8 probably due to partial permeabilization of the blood-brain barrier in tumors and their vasculature that allow drug penetration and permit antitumor activity until biochemical resistance emerges, limiting the duration of control. Because the mechanisms of immune checkpoint blockade include relatively slow onset of action and T-lymphocyte migration into tumors, 9 clinical and radiographic assessments of these therapies need to incorporate novel imaging strategies, such as those proposed by the Response Assessment in Neuro-Oncology group.
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Appropriate to current evidence-based recommendations, the authors limit their discussion of locoregional management to mainly clinical trials that pooled patients with melanoma with those who had other malignancies and studied surgery, stereotactic radiosurgery, and whole-brain radiotherapy in various combinations for patients with numbers and sizes of brain metastases. Except for increased skin toxicity with BRAF inhibitors, little to no interaction is currently known that would contraindicate the initiation or continuation of systemic therapy for patients with melanoma who need stereotactic radiosurgery for brain metastases.
A list of currently accruing clinical trials for patients with melanoma with brain metastases is provided as Table 2 in Chukwueke et al, 1 an interesting supplement to the text that should be considered of temporary value because of rapid turnover of clinical trials. Practical questions that have yet to be studied prospectively include the timing and type of screening and surveillance for brain metastases. Some clinical experts have advocated screening early and often for patients without evidence of metastatic disease and then managing aggressively with multimodality therapies when small, asymptomatic brain metastases are found.
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However, the brain is rarely an isolated site of metastatic melanoma, so in the absence of a trial to evaluate this approach, most others advocate that neurologically intact patients undergo gadolinium-enhanced brain magnetic resonance imaging only at first systemic relapse and then at any point of progression when a new therapy is planned. Breakthrough brain metastases during control of extracranial disease with systemic therapy occur not infrequently, but routine brain imaging in responders is of unproven patient benefit. Discussion of the emerging concepts of melanoma molecular biology and immunology applied to brain metastases would have greatly enriched this brief review. For laboratory scientists, molecular pathologists, and clinicians who manage these patients-surgeons, radiation oncologists, and medical oncologists-there is a desperate and immediate need for integration of several hypotheses and existing data to explain when and where metastases originate, what events occur before their detection, and how their molecular biology differs from that of other metastases and other cancers. It will be important to apply these principles to continue the rapid therapeutic progress that has occurred in melanoma metastatic to the brain.
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